Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06788938 · ClinicalTrials.gov registry record · Phase 2
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
A Phase 2 study of Advanced Tumors and DLL3-expressing Tumors, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 5
- Study locations
NCT06788938 is a Phase 2 study of Advanced Tumors and DLL3-expressing Tumors that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 29 participants. The trial reports 5 study locations across 1 state.
The verdict
NCT06788938, a Phase 2 study of Advanced Tumors and DLL3-expressing Tumors, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.
Conditions Studied
Interventions
- DRUG Tarlatamab treatment
Study Locations (5)
California
- UC Davis Comprehensive Cancer Center - Davis
- UCI Health Chao Family Comprehensive Cancer Center - Irvine
- University of California at Los Angeles - Los Angeles
- UC San Diego Moores Cancer Center - San Diego
- University of California at San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2029-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06788938
The ClinicalTrials.gov registry entry for NCT06788938 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Tumors appearing as the primary indexed condition, and to 1 intervention - of which Tarlatamab treatment is the first listed.
NCT06788938 reports 5 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06788938 about?
NCT06788938 is a clinical study titled "Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms". This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for...
What is the current status of trial NCT06788938?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2025-03-21. Estimated completion is 2029-04-24.
What conditions does trial NCT06788938 study?
This clinical trial studies the following conditions: Advanced Tumors, DLL3-expressing Tumors.
What interventions are being tested in trial NCT06788938?
The interventions under investigation include: Tarlatamab treatment (DRUG).
Who is sponsoring clinical trial NCT06788938?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06788938 being conducted?
This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.